J V Melo

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

David M. Ross, Susan Branford, John F. Seymour et al. · Leukemia · 2010 · 266 citations

Persistent Leukemia, Chromatin, Chronic Myeloid Leukemia +11

An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders.

Nicholas C.P. Cross, J V Melo, J M Goldman · PubMed · 1994 · 261 citations

Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprograming

Fanyu Zhao, Anthony Mancuso, Thi Bui et al. · Oncogene · 2010 · 175 citations · Full text

Imatinib Resistance, Bcr-abl Upregulation, Systems Biology +13

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

Jamshid S. Khorashad, Mona Anand, David Marin et al. · Leukemia · 2006 · 148 citations

Hematological Malignancy, Clinical Resistance, Health Sciences +9

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro

Kate Cwynarski, R. Laylor, Eugenio Macchiarulo et al. · Leukemia · 2004 · 132 citations · Full text

T-regulatory Cell, Immunology, Normal T +8